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 ABSTRACT
Introduction: Malignancy management in renal transplant recipients is becoming a major factor affecting long-
-term patient survival. Thus, we intended to evaluate both incidence and prognosis of malignant diseases following 
renal transplantation at a single centre in Portugal. Methods: We studied retrospectively the 2,358 patients who 
underwent kidney transplantation (KT) between 1983 and 2014. Apart from descriptive analysis, both demographic 
and clinical characteristics of cancer and non -cancer cancer patients were compared. Results: During a median 
follow -up of 118 (IQR 57 -179) months, 139 patients (5.8%) developed 158 de novo malignancies, with a median 
time from KT to diagnosis of 76..5 (IQR 21.0 -132.0) months. When compared to non -cancer patients, they were 
older at KT date, had longer graft survival and a lower living donor recipients’ prevalence. As for post -transplant 
malignancies analysis, the most common were non -cutaneous non -lymphomatous cancers (49.4%, n=78), skin 
cancers (35.4%, n=56) and post -transplant lymphoproliferative disorders (9.5%, n=15). Considering specific diag-
nosis, squamous cell carcinoma and basal cell carcinoma with 17.1% and 16.5% respectively, and non -Hodgkin 
lymphomas with 7.6%, were the most frequent. Global mortality among cancer patients was 36.0%, with a median 
time of 9.7 (IQR 1.9 -17.5) months from time of diagnosis to death. As for survival analysis, cancer patient survival 
was significantly lower while censored graft survival was significantly higher in this group. Conclusion: Incidence 
and characteristics of malignancy following renal transplantation in our unit are similar to those globally described, 
despite some traits probably a result of specific ethnic and environmental characteristics.
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 INTRODUCTION
Outcomes in kidney transplantation have been 
improving considerably over the past decades follow-
ing the introduction of new immunosuppressive drugs, 
namely in terms of morbidity and mortality from graft 
dysfunction and failure1. Nonetheless, there are some 
drawbacks arising from long -term immunosuppres-
sion, such as increased cardiovascular risk and 
transplant -related malignancies. For the latter, we 
must bear in mind that compared to the general 
population, renal transplant recipients are at a 3 to 5 
times higher risk of de novo malignancies, which often 
assume more aggressive behaviour and worse prog-
nosis2. Undeniably, malignancy management has 
become a vital piece of these patients’ medical follow-
-up, as it is fast becoming one of the major factors 
affecting long -term survival3. Thus, underlining the 
importance of an accurate knowledge of this subject, 
the present study’s focus was on evaluating both inci-
dence and prognosis of malignant diseases following 
renal transplantation at a single centre in Portugal.
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 SUBJECTS AND METHODS
This retrospective study identified all patients who 
underwent kidney transplantation between May 1983 
and December 2014 in the Transplant Department of 
Centro Hospitalar do Porto, Portugal. During this time 
period, a total of 2,358 kidney transplants were per-
formed, including children (<16 years) and adult 
patients (≥16 years). The maintenance immunosup-
pression varied during the follow -up period as the study 
covered a large period of time. The regimens comprised 
azathioprine (Aza) + prednisolone; cyclosporine (CSA) 
+ Aza + prednisolone; CSA vs tacrolimus (FK) + mycophe-
nolate mofetil (MMF) + prednisolone; sirolimus + CSA 
+ prednisolone. Descriptive analysis was used to sum-
marise baseline data as well as clinical data related to 
de novo malignancies, along with comparison between 
demographic features and clinical characteristics of 
cancer versus non -cancer patients. Kaplan -Meier analy-
sis was used to estimate overall cumulative patient and 
graft survivals. All statistical analysis was performed 
using SPSS software (Statistical Package for the Social 
Sciences, version 22.0, Evanston, III, United States), 
considering a p value <.05 as statistically significant.
 RESULTS
In our 32 -year experience, a total of 2,358 kidney 
transplant recipients were kept under follow -up with 
a median graft survival of 94.0 (Interquartile range [IQR] 
39.0 -149.0) months. Baseline characteristics of the 
study population are summarised in Table I. Among 
the total sample, 58.2% were male with a median age 
of 41.32 (IQR 32.4 -50.2) years at the time of 
transplantation (with a total of 152 patients being trans-
planted at a paediatric age). A total of 217 (9.2%) cases 
involved a living donor and 176 (7.5%) patients received 
a combined pancreas -kidney transplant. During the 
aforementioned period, 139 patients (5.8%) developed 
de novo malignancies, with a male predominance (n= 
86, 61.9%) and a median time from transplantation to 
diagnosis of 76.5 (IQR 21.0 -132.0) months. Among all 
the patients, 15 (10.8%) presented multiple de novo 
malignancies.
Statistical comparison between cancer and non-
-cancer patients evidenced no significant differences 
in recipient gender, dialysis vintage, number of kidney 
transplants, donor age and gender, history of previous 
acute rejection episodes or greater human leucocyte 
antigen (HLA) mismatches. Of the characteristics’ dis-
parities that achieved statistical significance between 
both cancer and non -cancer patients, we highlight 
recipient age, graft survival and donor type, as cancer 
patients were older at kidney transplantation (KT) date 
(46.97 [IQR 37.9 -56.1] vs 40.96 [IQR 32.2 -49.6] years, 
p<.001), had longer graft survival (147,00 [IQR 91.0-
-203.0] vs 93,00 [IQR 38.5 -147.5], p<.001) and there 
was a lower prevalence of living donor recipients (n=2, 
1.4% vs n=214, 10.1%, p=.001).
Focusing primarily on post -transplant malignancies 
(table II), the most common were non -cutaneous non-
-lymphomatous cancers (49.4%, n=78), herein gathered 
as a major group; skin cancers (35.4%, n=56); and post-
-transplant lymphoproliferative disorders (PTLD) (9.5%, 
n=15). Focusing on the first group, the three specific 
tumours that stood out were breast cancer (n= 11, 
14.1%), colorectal cancer (n=10, 12.8%) and renal cell 
carcinoma (RCC) (n=9, 11.5%); while among the skin 
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Table I
Demographic and Clinical Characteristics of Kidney Transplant Recipients
Characteristics
Total
(n=2358)
With Cancer
(n=139)
Without Cancer (n=2219) P Value
Recipient age (y) 41.3 (IQR 32.4 -50.2) 47.0 (IQR 37.9 -56.1) 41.0 (IQR 32.3 -49.7) <.001
Recipient gender (male:female) 1387 (58.2): 971 (41.2) 86(61.9): 53 (38.1) 1301(58.6): 918 (41.4) .451
Dialysis vintage (mo) 34.0 (IQR 9.5 -58.5) 30.0 (IQR 6.0 -54.0) 35.0 (IQR 10.0 -60.0) .622
Living donor 216 (9.2%) 2 (1.4%) 214 (10.1%) .001
No of KT (>1) 436 (18.5%) 14 (11.2%) 422 (19.0%) .208
Donor age (y) 36.0 (IQR 22.0 -50.0) 32.0 (IQR 20.5 -43.5) 36 (IQR 22.0 -50.0) .441
Donor gender (male:female) 1526 (69.7): 664(30.3) 96 (76.8): 29 (23.2) 1430 (69.2): 635 (30.8) .074
Graft survival (mo) 94.0 (IQR 38.5 -149.5) 147.0 (IQR 91.0 -203.0) 93.0 (IQR 38.5 -147.5) <.001
AR episode 471 (20.0%) 441 (19.0%) 30 (21.6%) .504
No of HLA mismatch (>3) 914 (41.5%) 51 (38.1%) 863 (41.7%) .403
Abbreviations: y, years; mo, months; No, number; KT, kidney transplants; AR, acute rejection; HLA, human leucocyte antigen.
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cancers, squamous cell carcinoma (SCC) and basal cell 
carcinoma (BCC) with 27 (48.2%) and 26 (46.4%) cases 
respectively. Of the latter group, non -Hodgkin lympho-
mas (NHL) made up 85.7% (n=12). An important remark 
on two cases (an ovarian adenocarcinoma and a colon 
adenocarcinoma) where time of diagnosis coincided 
with that of transplantation, meaning both cancers 
preceded immunosuppression. The median time 
between transplantation and malignancy diagnosis was 
76.5 (IQR 21.0 -132.0) months, with briefer times among 
non -cutaneous non -lymphomatous cancers (73.0, IQR 
20.0 -126.0), Kaposi’s sarcomas (KS) (20.50 ± 13.1) and 
those of occult primary cause (6.0 ± 2.8). As for gender 
distribution, and focusing on malignancies as a whole, 
there was a clear male predominance almost at a 2:1 
ratio. Among skin cancers and PTLD, there was a female 
predominance (~3:1 and 4:1, respectively), whereas 
among non -cutaneous non -lymphomatous cancers the 
male/female rates were quite similar. Considering 
global mortality in the de novo malignancies’ group, 
we registered 50 deaths, accounting for 36.0% mortality 
Malignancy after renal transplantation: a single ‑centre experience
Figure 1
Cumulative patient survival rates analyzed by log -rank test
 
Table II
Type of malignancy
Type of malignancy n (%)
Gender  
(male:female)
Time between KT and Dx 
(mo) 
Death related to malignancy: 
n (%)
Non -cutaneous Non -lymphomatous 78 (49.4) 38:40 * 73.0 (IQR 20.0 -126.0) 29 (37.2) *
Breast 11 (7.0) 1:10 37.0 (IQR  -15.5 -89.5) 3 (27.3)
Colorectal 10 (6.4) 5:5 137.7 ± 86.7 4 (40.0)
Renal 9 (5.7) 7:2 103.4 ± 46.6 1 (11.1)
Stomach 6 (3.8) 5:1 60.5 ± 49.4 3 (50.0)
Anogenital carcinomas 6 (3.8) 0:6 39.7 ± 37.5 0 (0.0)
Prostate 5 (3.1) 5:0 102.6 ± 44.9 1 (20.0)
Uterine cervical carcinomas 4 (2.5) 0:4 59.0 (IQR  -33.5 -151.5) 1 (25.0)
Ovary 4 (2.5) 0:4 114.3 ± 97.7 2 (50.0)
Thyroid 4 (2.5) 1:3 97.5 ± 65.6 1 (25.0)
Bladder 3 (1.9) 3:0 53.7 ± 68.1 2 (66.7)
Hepatocellular 3 (1.9) 2:1 141.7 ± 39.7 3 (100.0)
Sarcomas (excluding KS) 3 (1.9) 2:1 53.0 ± 16.1 3 (100.0)
Other 10 (6.4) 7:3 101.4 ± 82.4 5 (50.0)
Skin cancer 56 (35.4) 41:15 * 95.5 ± 66.0 * 2 (3.6)
SCC 27 (17.1) 21:6 100.9 ± 69.8 1 (3.7)
BCC 26 (16.5) 17:9 94.0 ± 61.6 0 (0.0)
Melanoma 2 (1.2) 2:0 85.5 ± 96.9 1 (50.0)
Malignant histiocytoma 1 (0.6) 1:0 9.0 0 (0.0)
PTLD 15 (9.5) 12:3 9 (60.0) *
NHL 12 (7.6) 10:2 115.0 ± 70.0 7 (58.3)
HL 3 (1.9) 2:1 201.7 ± 109.2 2 (66.7)
Kaposi’s sarcoma 6 (3.8) 5:1 20.50 ± 13.1 0 (0.0)
Occult primary 3 (1.9) 3:0 6.0 ± 2.8 3 (100.0)
Total 158100 99:59 76.5 (IQR 21.0 -132.0) 43 (27.2)
Abbreviations: SCC, squamous cell carcinoma; BCC, basal cell carcinoma; PTLD, posttransplant lymphoproliferative diseases; KT, kidney transplant; mo, months; *, p value<.05 when 
comparing between the whole malignancies’ sample
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in this group, though 43 (86.0%) were directly related 
to malignancy, with a median time of 9.7 (IQR 1.9 -17.5) 
months between diagnosis and death. As for major 
subgroup analysis, given its higher inherent mortality, 
the PTLD group had a 60% mortality (n=9), non-
-cutaneous non -lymphomatous cancers had 37.2% 
(n=29) while skin cancers were at the opposite end 
with 3.6% (n=2). The overall cumulative patient and 
graft survival rates comparing cancer and non -cancer 
groups are shown as Kaplan -Meier curves in Fig. 1 and 
Fig. 2, respectively.
 DISCUSSION
There is cumulative evidence behind the higher risk 
of de novo malignancies of renal transplant recipients 
when compared to the general population, though most 
of the information derives primarily from registries4 -6 
and is therefore subject to some bias by way of under-
reporting, incomplete data on reported malignancies 
and occasionally inclusion of only first malignancy or 
exclusion of some types of malignancies7. Nonetheless 
it is valid information from which one can compare and 
ascertain subjacent characteristics from the study popu-
lation. Thus, when focusing on our data, our incidence 
of de novo malignancies of 5.8% was similar to other 
reports from Europe (1% to 9%), the United States (6%) 
but lower than those from Australia (18 to 28%)8,9. 
These numbers reveal an increased incidence when 
matched to general population, since considering North 
Region Cancer Registry of Portugal (RORENO)10,11 as a 
population -based cancer registry that covers that of our 
Transplant Unit’s area of influence and comprises data 
covering most of the follow -up, we managed to infer a 
standardized incidence ratio (SIR) of 188 for all cancers 
except non -melanoma skin, indicating an 88% increase 
in these cancers when compared to the general popula-
tion. However such excess arises from particular malig-
nancies matching those suggested by the literature 
findings. Accordingly, when considering specific malig-
nancies we found that skin cancers, except for melano-
mas, were the most frequent type in KT recipients, fol-
lowed by PTLDs. The remaining spectrum of cancers 
was also consistent with the literature data, namely for 
the high frequency of KS, RCC, anogenital, bladder and 
hepatocellular carcinomas. Unsurprisingly, virus -related 
cancers were frequent, such as NHL associated with 
infection with Epstein -Barr virus (EBV) and KS associated 
with human herpes virus type 8 (HHV -8) infection. How-
ever, two comments must be made. KS had an overall 
incidence less than 0.3%, in the lower end of multiple 
studies with incidences ranging from 0.5% for Western 
and Northern countries to approximately 5% in the 
Mediterranean regions12, probably a result of low sero-
prevalence of HHV -8. Whereas for PTLD one would 
expect a shorter time to development (the literature’s 
average of 32 months after transplantation versus the 
observed mean of 132.3 ± 82.7 months). The incidence 
of lymphoma development has been reported as highest 
during the first year after transplantation, when the risk 
of primary viral infection is highest and the level of 
immunosuppression is greatest13.
As seen by the Kaplan -Meier curves, malignancy 
ostensibly affects long -term patient survival. However, 
in the censored graft survival curve, we observed an 
inversion of the lines, as the subgroup of cancer patients 
showed a longer graft survival (p<.001), probably arising 
from the initial difference between both groups as seen 
by the similar decline rates all throughout follow -up, 
consubstantiating the suggestion that longer immuno-
suppression and follow -up raise the risk of de novo 
malignancies and not the way around.
 CONCLUSION
As a single -centre experience, this study supplies valid 
information with inherent limitations. In a global analy-
sis, overall patient and graft survival rates had markedly 
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Figure 2
Cumulative censored graft survival rates analyzed by log -rank test
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good results, yet de novo malignancies following renal 
transplantation are an important factor affecting long-
-term survival, given its greater risk when there is longer 
immunosuppression. Ultimately, the incidence and 
characteristics of malignancy following renal transplan-
tation in our unit are similar to those described in other 
series. However, some of the trends expressed in larger 
registries are not followed, probably a result of specific 
ethnic and environment characteristics.
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